Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Study sponsor: Nuvation Bio Inc. · NUVB
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2030-08-30Estimated
Enrollment · participants180Estimated
Source updated2026-05-19Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.